These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 37246403)

  • 21. Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression.
    Musso G; Sircana A; Saba F; Cassader M; Gambino R
    PLoS Med; 2020 Dec; 17(12):e1003461. PubMed ID: 33373368
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative effectiveness and safety of sodium-glucose cotransporter-2 inhibitors versus metformin in patients with type 2 diabetes: An observational study using data from routine care.
    Fralick M; Schneeweiss S; Redelmeier DA; Razak F; Gomes T; Patorno E
    Diabetes Obes Metab; 2021 Oct; 23(10):2320-2328. PubMed ID: 34169619
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.
    Neuen BL; Young T; Heerspink HJL; Neal B; Perkovic V; Billot L; Mahaffey KW; Charytan DM; Wheeler DC; Arnott C; Bompoint S; Levin A; Jardine MJ
    Lancet Diabetes Endocrinol; 2019 Nov; 7(11):845-854. PubMed ID: 31495651
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Renal outcomes and all-cause death associated with sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL 3 Korea).
    Koh ES; Han K; Nam YS; Wittbrodt ET; Fenici P; Kosiborod MN; Heerspink HJL; Yoo SJ; Kwon HS
    Diabetes Obes Metab; 2021 Feb; 23(2):455-466. PubMed ID: 33118320
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative efficacy of novel antidiabetic drugs on cardiovascular and renal outcomes in patients with diabetic kidney disease: A systematic review and network meta-analysis.
    Cao H; Liu T; Wang L; Ji Q
    Diabetes Obes Metab; 2022 Aug; 24(8):1448-1457. PubMed ID: 35665989
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The efficacy and safety of SGLT2 inhibitors in patients with non-diabetic chronic kidney disease: a systematic review and meta-analysis.
    Ma C; Li X; Li W; Li Y; Shui F; Zhu P
    Int Urol Nephrol; 2023 Dec; 55(12):3167-3174. PubMed ID: 37046125
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes: a systematic review and meta-analysis of randomised placebo-controlled trials.
    Tsai WC; Hsu SP; Chiu YL; Yang JY; Pai MF; Ko MJ; Tu YK; Hung KY; Chien KL; Peng YS; Wu HY
    BMJ Open; 2022 Oct; 12(10):e060655. PubMed ID: 36241355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Dipeptidyl Peptidase 4 Inhibitors and Sulfonylureas on the Risk of Diabetic Ketoacidosis.
    Dawwas GK; Flory JH; Hennessy S; Leonard CE; Lewis JD
    Diabetes Care; 2022 Apr; 45(4):919-927. PubMed ID: 35147696
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and moderate renal function impairment: A systematic review and meta-analysis.
    Zhang L; Zhang M; Lv Q; Tong N
    Diabetes Res Clin Pract; 2018 Jun; 140():295-303. PubMed ID: 29649541
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ
    Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stabilization of kidney function and reduction in heart failure events with sodium-glucose co-transporter 2 inhibitors: A meta-analysis and meta-regression analysis.
    Keidai Y; Yoshiji S; Hasebe M; Minamino H; Murakami T; Tanaka D; Fujita Y; Inagaki N
    Diabetes Obes Metab; 2023 Sep; 25(9):2505-2513. PubMed ID: 37217461
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Adverse Events Associated with Sodium-Glucose Cotransporter 2 Inhibitors: A Meta-Analysis Involving 10 Randomized Clinical Trials and 71 553 Individuals.
    Lin DS; Lee JK; Chen WJ
    J Clin Endocrinol Metab; 2021 Jun; 106(7):2133-2145. PubMed ID: 33895840
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors and Combined SGLT1/2 Inhibitors on Cardiovascular, Metabolic, Renal, and Safety Outcomes in Patients with Diabetes: A Network Meta-Analysis of 111 Randomized Controlled Trials.
    Teo YN; Ting AZH; Teo YH; Chong EY; Tan JTA; Syn NL; Chia AZQ; Ong HT; Cheong AJY; Li TY; Poh KK; Yeo TC; Chan MY; Wong RCC; Chai P; Sia CH
    Am J Cardiovasc Drugs; 2022 May; 22(3):299-323. PubMed ID: 35316484
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: A systematic review and meta-analysis.
    Seidu S; Kunutsor SK; Cos X; Gillani S; Khunti K;
    Prim Care Diabetes; 2018 Jun; 12(3):265-283. PubMed ID: 29482993
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety of SGLT2 Inhibitors in Three Chronic Diseases.
    Ge S; Liu R; Mao Y; Geng C; Wang H; Song K; Tian QB
    Int Heart J; 2023; 64(2):246-251. PubMed ID: 37005318
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sodium-glucose cotransporter-2 inhibitors and kidney outcomes in real-world type 2 diabetes populations: A systematic review and meta-analysis of observational studies.
    Forbes AK; Suckling RJ; Hinton W; Feher MD; Banerjee D; Cole NI; de Lusignan S; Swift PA
    Diabetes Obes Metab; 2023 Aug; 25(8):2310-2330. PubMed ID: 37202870
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis.
    Salah HM; Al'Aref SJ; Khan MS; Al-Hawwas M; Vallurupalli S; Mehta JL; Mounsey JP; Greene SJ; McGuire DK; Lopes RD; Fudim M
    Cardiovasc Diabetol; 2022 Feb; 21(1):20. PubMed ID: 35123480
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of SGLT2 Inhibitors in Patients with Type 1 Diabetes: A Meta-analysis of Randomized Controlled Trials.
    Yang Y; Pan H; Wang B; Chen S; Zhu H
    Chin Med Sci J; 2017 Apr; 32(1):22-7. PubMed ID: 28399981
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-dose sodium-glucose co-transporter-2 inhibitors are superior in type 2 diabetes: A meta-analysis of randomized clinical trials.
    Shi FH; Li H; Shen L; Fu JJ; Ma J; Gu ZC; Lin HW
    Diabetes Obes Metab; 2021 Sep; 23(9):2125-2136. PubMed ID: 34048142
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sodium-glucose cotransporter-2 inhibitors (SGLT2) in frail or older people with type 2 diabetes and heart failure: a systematic review and meta-analysis.
    Aldafas R; Crabtree T; Alkharaiji M; Vinogradova Y; Idris I
    Age Ageing; 2024 Jan; 53(1):. PubMed ID: 38287703
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.